The Good: Facebook Facebook’s market value passed $1 trillion today following a landmark judicial dismissal. The decision, which came from a US District Court judge, dismissed parallel antitrust complaints against the company which had been filed by both the Federal Trade Commission and a conglomerate of state attorney generals from 48 states. Last December, the FTC alleged that Facebook was “illegally maintaining its personal social networking monopoly through a yearslong course of anticompetitive strategy.” This supposed strategy included acquisitions of Instagram in 2012 and Whatsapp 2012. The FTC advocated for forcing divestitures of both Facebook subsidiaries while demanding Facebook seek prior notice for future deals. All of these arguments were rejected. Facebook shares bounded up 4.2% on the news. The anti-antitrust decision also sent shares of other big tech companies, including Apple, Microsoft and Amazon, up 1%. The Bad: Vaccine Producers What’s good for the world is not always good for business. Such is the case with major Covid-19 vaccine manufacturers following a potentially business-changing study which suggests we may not need regular Covid-19 boosters to stave off the pandemic. Companies which may be effected include Moderna and Pfizer, both of which developed world-changing vaccines over the last year. The bull cases for both includes the belief that a need for continual boosters, which could, in theory, help maintain immunity and be adapted to fight off rising variants. While both companies insist on the need for boosters, the US government hasn’t yet been convinced. The vaccines’ effectiveness in the coming months will tell us, and both companies, if there’s a need for a strategy adjustment. The Ugly: Boeing Boeing’s continued struggles, following two high-profile crashes of its vaunted new generation 737 MAX planes, got a little more complicated today as its latest 777 jet, the 777X, saw delayed approval by the Federal Aviation Administration. The FAA told the company that the jet likely won’t be approved for commercial use until mid-2023, causing the stock to fall. The 777X took its initial test flight back in January 2020, which would have put regulatory approval on track for mid-2021, but the approval process has slowed thanks to the problems with Boeing’s 737 MAX. A Boeing spokesman assured investors that this updated timeline was in line with expectations.